Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus CapeOx vs CapeOx plus placebo in ErbB2-positive advanced gastric or esophagogastric adenocarcinoma
2007-005725-29Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma comparing CapeOx plus lapatinib with CapeOx plus placebo (2 arms). Primary endpoint: Progression-free survival. Started Mar 2008; status: completed.
02
Drugs
lapatinib
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2007-005725-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005725-29.